Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18895296 | IMMUNE CELLS DEFECTIVE FOR SUV39H1 | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18773146 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18596451 | VACCINATION WITH mRNA-CODED ANTIGENS | March 2024 | May 2024 | Allow | 2 | 1 | 0 | No | No |
| 18474533 | Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use Thereof | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18468652 | CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1 | September 2023 | July 2024 | Allow | 10 | 1 | 1 | No | No |
| 18358358 | MUTATED POLYPEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | July 2023 | November 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18339157 | METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY | June 2023 | November 2023 | Allow | 5 | 0 | 0 | No | No |
| 18318507 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | May 2023 | January 2024 | Allow | 8 | 1 | 0 | No | No |
| 18118558 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | March 2023 | December 2023 | Allow | 9 | 1 | 0 | No | No |
| 18158173 | ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | January 2023 | December 2024 | Allow | 23 | 3 | 1 | No | No |
| 18157421 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | January 2023 | August 2023 | Allow | 7 | 0 | 0 | No | No |
| 18157052 | METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION | January 2023 | January 2025 | Allow | 24 | 2 | 1 | No | No |
| 18068376 | METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX FUSION PROTEINS | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 18080811 | EXPANDABLE CELL POPULATIONS FROM BRAIN BIOPSIES OF LIVING SUBJECTS | December 2022 | November 2024 | Allow | 23 | 0 | 0 | No | No |
| 18066175 | METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF) | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17974123 | METHOD OF EXPANDING AND GENERATING A POPULATION OF CYTOKINE-INDUCED KILLER CELLS FROM PERIPHERAL BLOOD | October 2022 | December 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17971016 | METHOD AND DEVICE FOR REMOVAL OF CIRCULATING CELL FREE DNA | October 2022 | March 2024 | Allow | 17 | 1 | 2 | No | No |
| 17938501 | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof | October 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17956257 | Phagemid Vector | September 2022 | February 2025 | Allow | 29 | 1 | 0 | No | No |
| 17823186 | HUMANIZED IL-4 AND IL-4Ra ANIMALS | August 2022 | January 2025 | Allow | 29 | 1 | 0 | No | No |
| 17893052 | NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS | August 2022 | February 2025 | Allow | 30 | 1 | 0 | No | No |
| 17879559 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | August 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17871383 | METHODS AND COMPOSITIONS FOR GENERATING PACEMAKER CELLS | July 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17813530 | RNA-CODED ANTIBODY | July 2022 | March 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17792713 | PREPARATION METHOD AND SYSTEM FOR RECOMBINANT ADENO-ASSOCIATED VIRUS, AND RECOMBINANT BACMID | July 2022 | March 2025 | Allow | 32 | 2 | 0 | No | No |
| 17862666 | RAPID ASSAY FOR DETECTION OF SARS-CoV-2 ANTIBODIES | July 2022 | December 2024 | Allow | 29 | 1 | 0 | No | No |
| 17742042 | METHOD FOR SELECTING CELLS, METHOD FOR PRODUCING NUCLEIC ACID, METHOD FOR PRODUCING RECOMBINANT CELLS, METHOD FOR PRODUCING TARGET SUBSTANCE, METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION, AND REAGENT | May 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17741024 | VECTORS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | May 2022 | March 2025 | Allow | 35 | 2 | 0 | No | No |
| 17724423 | METHODS OF B CELL EXPANSION FOR USE IN CELL THERAPY | April 2022 | February 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17659598 | VECTORS AND METHODS FOR REGENERATIVE THERAPY | April 2022 | May 2025 | Allow | 37 | 2 | 0 | No | No |
| 17659007 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF CD79A AND CD79B | April 2022 | December 2024 | Allow | 33 | 1 | 0 | No | No |
| 17715710 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | April 2022 | October 2023 | Allow | 18 | 2 | 1 | No | No |
| 17701488 | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA | March 2022 | May 2025 | Allow | 38 | 2 | 0 | No | No |
| 17591227 | BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL | February 2022 | October 2024 | Allow | 32 | 1 | 0 | No | No |
| 17571325 | CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY | January 2022 | February 2025 | Allow | 37 | 3 | 0 | No | No |
| 17570352 | Novel Codon-Optimized CFTR MRNA | January 2022 | June 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17561659 | METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY | December 2021 | February 2024 | Allow | 26 | 2 | 0 | No | No |
| 17558977 | COMPOSITIONS FOR MODULATING AN XBP1 PATHWAY IN A KERATINOCYTE AND METHODS OF USE | December 2021 | September 2024 | Allow | 33 | 2 | 0 | No | No |
| 17528550 | HIGH THROUGHPUT CLONING OF PAIRED BIPARTITE IMMUNORECEPTOR POLYNUCLEOTIDES AND APPLICATIONS THEREOF | November 2021 | June 2024 | Allow | 31 | 2 | 0 | No | No |
| 17521509 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | November 2021 | April 2024 | Allow | 30 | 1 | 0 | No | No |
| 17514711 | MODIFIED AAV CAPSIDS AND USES THEREOF | October 2021 | February 2024 | Allow | 28 | 1 | 0 | No | No |
| 17475116 | SIGLEC TRANSGENIC MICE AND METHODS OF USE THEREOF | September 2021 | March 2024 | Allow | 30 | 1 | 0 | No | No |
| 17394492 | HUMANIZED IL-4 AND IL-4Ra ANIMALS | August 2021 | November 2023 | Allow | 28 | 1 | 0 | No | No |
| 17387892 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | July 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17383052 | GENE THERAPY FOR RETINITIS PIGMENTOSA | July 2021 | September 2024 | Allow | 38 | 1 | 0 | No | No |
| 17376484 | Co-Expression of Magnetotactic Bacterial Genes and Genes Encoding Iron Handling Proteins in Cells | July 2021 | February 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17374147 | RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF MYOTILIN | July 2021 | February 2025 | Allow | 43 | 2 | 1 | No | No |
| 17366827 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME | July 2021 | January 2024 | Allow | 30 | 1 | 0 | No | No |
| 17332853 | CHIMERIC ANTIGEN RECEPTORS TARGETING FC RECEPTOR-LIKE 5 AND USES THEREOF | May 2021 | June 2024 | Allow | 37 | 0 | 1 | No | No |
| 17295588 | Methods and Compositions for Treating Osteoarthritis | May 2021 | April 2025 | Allow | 46 | 2 | 1 | No | No |
| 17306376 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | May 2021 | January 2024 | Allow | 32 | 1 | 0 | No | No |
| 17211559 | CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1 | March 2021 | November 2023 | Allow | 32 | 1 | 0 | No | No |
| 17275832 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING MRNA THERAPEUTICS | March 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17270606 | BLOOD-BRAIN BARRIER PERMEABLE APTAMER AND APPLICATION THEREOF | February 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17250561 | VIRAL VECTORS ENCODING CANCER/TESTIS ANTIGENS FOR USE IN A METHOD OF PREVENTION OR TREATMENT OF CANCER | February 2021 | October 2024 | Allow | 44 | 1 | 0 | No | No |
| 17115565 | CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF | December 2020 | March 2025 | Allow | 52 | 3 | 0 | No | No |
| 17067614 | VACCINATION WITH mRNA-CODED ANTIGENS | October 2020 | February 2024 | Abandon | 41 | 2 | 0 | No | Yes |
| 17066134 | SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE | October 2020 | May 2025 | Abandon | 56 | 3 | 0 | No | Yes |
| 17065003 | TREATMENT OF RETINITIS PIGMENTOSA | October 2020 | January 2025 | Abandon | 52 | 0 | 1 | No | No |
| 16989686 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | August 2020 | July 2024 | Abandon | 47 | 2 | 0 | No | Yes |
| 16987835 | Mutant IDH1 Specific T Cell Receptor | August 2020 | November 2024 | Abandon | 51 | 0 | 1 | No | No |
| 16934925 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | July 2020 | May 2023 | Allow | 34 | 2 | 0 | No | No |
| 16934606 | ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS | July 2020 | March 2025 | Allow | 56 | 3 | 1 | No | No |
| 16767497 | Reprogrammed T Cell-Like NK Cells | May 2020 | March 2025 | Allow | 57 | 2 | 1 | No | No |
| 16757263 | VECTORS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | April 2020 | May 2024 | Allow | 49 | 1 | 0 | No | No |
| 16832321 | HLA G-MODIFIED CELLS AND METHODS | March 2020 | March 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16643251 | DOUBLE SELECTION HDR CRISPR-BASED EDITING | February 2020 | September 2024 | Abandon | 54 | 3 | 1 | Yes | No |
| 16744296 | METHOD FOR UTILIZING ENGINEERED DENDRITIC CELLS TO INDUCE GUT-HOMING REGULATORY T CELLS AND TREAT GUT INFLAMMATION | January 2020 | December 2024 | Allow | 59 | 4 | 0 | No | Yes |
| 16616099 | USE OF THE IL-15/IL-15RA COMPLEX IN THE GENERATION OF ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE IMMUNOTHERAPY | November 2019 | February 2025 | Allow | 60 | 2 | 1 | No | No |
| 16613187 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | November 2019 | January 2024 | Allow | 50 | 1 | 0 | No | No |
| 16474554 | BIFUNCTIONAL MOLECULE AND USE THEREOF | November 2019 | October 2024 | Allow | 60 | 2 | 1 | No | No |
| 16612632 | Systemic Delivery of Polypeptides | November 2019 | October 2024 | Abandon | 59 | 4 | 1 | No | No |
| 16679127 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | November 2019 | May 2024 | Abandon | 54 | 0 | 1 | No | No |
| 16516286 | IL-31 Improves Efficacy of Macrophage-Based Adoptive Cell Therapy for Cancer | July 2019 | February 2024 | Allow | 55 | 1 | 1 | No | No |
| 16516060 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | July 2019 | February 2024 | Allow | 55 | 1 | 1 | No | No |
| 16510818 | MENINGEAL REPAIR USING HUMAN UMBILICAL CORD PATCHES | July 2019 | May 2025 | Allow | 60 | 3 | 0 | No | No |
| 16322285 | TREATMENT OF CANCER USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH AN INHIBITOR OF A PRO-M2 MACROPHAGE MOLECULE | January 2019 | August 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16244909 | RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE GENE SEGMENTS | January 2019 | February 2024 | Allow | 60 | 8 | 0 | No | Yes |
| 16092946 | SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS | October 2018 | December 2023 | Allow | 60 | 2 | 1 | No | No |
| 16112282 | Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles And Uses Thereof In Autoimmune Diseases | August 2018 | October 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16069727 | Genome Editing for Treating Glioblastoma | July 2018 | March 2024 | Allow | 60 | 2 | 1 | No | No |
| 15770171 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | April 2018 | October 2023 | Allow | 60 | 3 | 1 | No | Yes |
| 15769241 | METHODS FOR GENERATING ENGINEERED HUMAN PRIMARY BLOOD DENDRITIC CELL LINES | April 2018 | October 2023 | Allow | 60 | 3 | 1 | No | No |
| 15756937 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | March 2018 | February 2024 | Allow | 60 | 3 | 1 | No | No |
| 15798619 | METHODS AND COMPOSITIONS FOR GENERATING PACEMAKER CELLS | October 2017 | February 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15664142 | METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS | July 2017 | October 2018 | Allow | 15 | 1 | 0 | No | No |
| 15650073 | HUMAN ARCAP TRANSGENIC MOUSE | July 2017 | March 2019 | Allow | 20 | 2 | 0 | No | No |
| 15452658 | VACCINATION WITH mRNA-CODED ANTIGENS | March 2017 | February 2024 | Allow | 60 | 6 | 1 | No | Yes |
| 15306682 | Gene Therapy | October 2016 | April 2019 | Allow | 29 | 3 | 0 | No | No |
| 15080020 | Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity | March 2016 | December 2016 | Allow | 13 | 1 | 0 | No | No |
| 15015458 | VACCINATION IN ELDERLY PATIENTS | February 2016 | August 2024 | Abandon | 60 | 8 | 0 | No | Yes |
| 14899601 | COVALENTLY CLOSED NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | December 2015 | November 2018 | Allow | 35 | 2 | 0 | No | No |
| 14796909 | Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity | July 2015 | March 2017 | Allow | 21 | 2 | 0 | No | No |
| 14665191 | Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity | March 2015 | December 2015 | Allow | 9 | 1 | 0 | No | No |
| 14489304 | Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine | September 2014 | April 2015 | Allow | 7 | 1 | 0 | No | No |
| 14179951 | Bovine Adeno-Associated Viral (BAAV) Vector and Uses Thereof | February 2014 | July 2015 | Allow | 17 | 2 | 0 | No | No |
| 14116539 | WDR13 AS A NOVEL BIOMARKER USEFUL FOR TREATING DIABETES AND CANCER | February 2014 | October 2015 | Allow | 23 | 1 | 0 | No | No |
| 14136076 | HIGH-THROUGHPUT ANTIBODY HUMANIZATION | December 2013 | September 2016 | Allow | 33 | 1 | 1 | No | No |
| 14022121 | METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS | September 2013 | January 2015 | Allow | 16 | 1 | 0 | No | No |
| 13933382 | AAV4 VECTOR AND USES THEREOF | July 2013 | March 2014 | Allow | 9 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BURKHART, MICHAEL D.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BURKHART, MICHAEL D works in Art Unit 1638 and has examined 198 patent applications in our dataset. With an allowance rate of 86.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner BURKHART, MICHAEL D's allowance rate of 86.9% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by BURKHART, MICHAEL D receive 2.09 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BURKHART, MICHAEL D is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +10.2% benefit to allowance rate for applications examined by BURKHART, MICHAEL D. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 24.8% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 46.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 33.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 70.4% of appeals filed. This is in the 52% percentile among all examiners. Of these withdrawals, 63.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 53.1% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 21.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.